Xencor (XNCR) Financials: History & Chart

Xencor, Inc.(XNCR)

Biotechnology · Pasadena, CA

$24.15-1.48 (-5.78%)

Delayed quote: Oct 6, 2026, 3:15 PM EDT

About Xencor, Inc.

Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.

Pasadena, CA

260 employees

www.xencor.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Bassil I. Dahiyat

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	104.97M	51.22M	4.52M	28.24M	21.00M	43.61M	32.73M	70.02M	17.80M
Cost of Goods Sold	59.51M	0.00	2.57M	2.58M	54.37M	2.65M	2.69M	0.00	58.23M
Gross Profit	45.46M	51.22M	1.95M	25.66M	-33.37M	40.95M	30.04M	70.02M	-40.43M
Gross Profit Margin	43.3%	100.0%	43.2%	90.9%	-158.9%	93.9%	91.8%	100.0%	-227.2%
Total Operating Expenses	261.54M	88.29M	79.81M	79.29M	14.15M	74.13M	73.22M	65.97M	14.77M
Research & Development	255.76M	71.91M	64.67M	64.82M	54.37M	61.66M	58.58M	51.06M	58.23M
Selling, General & Administrative	65.28M	16.38M	17.71M	17.04M	14.15M	15.12M	17.34M	14.91M	14.77M
Operating Income (EBIT)	-216.08M	-37.07M	-77.86M	-53.63M	-47.52M	-33.17M	-43.18M	4.05M	-55.20M
Operating Margin	-205.8%	-72.4%	-1724.1%	-189.9%	-226.3%	-76.1%	-131.9%	5.8%	-310.2%
Income Before Tax (EBT)	-160.85M	-21.92M	-128.64M	-4.27M	-6.03M	-31.07M	-48.27M	-52.63M	-47.44M
Interest Income	23.00M	4.80M	5.46M	6.20M	6.54M	7.25M	7.54M	8.16M	7.54M
Interest Expense	27.07M	7.35M	4.70M	7.35M	7.67M	8.24M	8.66M	33.93M	795K
Other Income/Expense	55.23M	15.15M	-50.77M	49.36M	41.49M	2.10M	-5.08M	-56.67M	7.75M
Net Income	-163.32M	-21.73M	-128.92M	-6.65M	-6.03M	-30.82M	-48.42M	-53.48M	-46.29M
Income Tax Expense	2.48M	-190K	280K	2.39M	0.00	-250K	367K	1.50M	0.00
Net Profit Margin	-155.6%	-42.4%	-2854.7%	-23.6%	-28.7%	-70.7%	-147.9%	-76.4%	-260.1%
EBITDA	-205.90M	-34.63M	-75.30M	-51.05M	-44.93M	-30.52M	-40.49M	7.04M	-52.14M
EBITDA Margin	-196.1%	-67.6%	-1667.3%	-180.8%	-214.0%	-70.0%	-123.7%	10.1%	-293.0%
Depreciation & Amortization	10.17M	2.44M	2.57M	2.58M	2.59M	2.65M	2.69M	2.99M	3.05M
EPS Basic	-2.17	-0.29	-1.71	-0.09	-0.08	-0.41	-0.66	-0.73	-0.71
EPS Diluted	-2.17	-0.29	-1.71	-0.09	-0.08	-0.41	-0.66	-0.73	-0.71
Weighted Average Basic Shares	75.86M	75.86M	75.25M	74.24M	74.41M	74.28M	73.67M	73.18M	64.02M
Weighted Average Diluted Shares	75.86M	75.86M	75.25M	74.24M	74.41M	74.28M	73.67M	73.18M	64.02M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	125.58M	110.49M	174.62M	164.58M	275.11M	122.69M	156.70M	40.60M
Cost of Goods Sold	10.51M	227.69M	0.00	199.56M	192.51M	169.80M	118.59M	97.50M
Gross Profit	115.06M	-117.19M	174.62M	-34.98M	82.60M	-47.11M	38.11M	-56.90M
Gross Profit Margin	91.6%	-106.1%	100.0%	-21.3%	30.0%	-38.4%	24.3%	-140.1%
Total Operating Expenses	292.57M	61.22M	306.98M	47.49M	38.84M	29.69M	24.29M	119.97M
Research & Development	239.43M	227.69M	253.60M	199.56M	192.51M	169.80M	118.59M	97.50M
Selling, General & Administrative	63.64M	58.89M	53.38M	47.49M	38.84M	29.69M	24.29M	22.47M
Operating Income (EBIT)	-177.50M	-178.41M	-132.36M	-82.47M	43.77M	-76.80M	13.82M	-79.37M
Operating Margin	-141.4%	-161.5%	-75.8%	-50.1%	15.9%	-62.6%	8.8%	-195.5%
Income Before Tax (EBT)	-89.42M	-234.92M	-119.63M	-54.51M	82.63M	-69.33M	27.19M	-70.41M
Interest Income	27.52M	31.93M	18.63M	4.82M	862K	7.26M	13.62M	9.10M
Interest Expense	31.93M	36.64M	N/A	N/A	13K	N/A	N/A	16K
Other Income/Expense	87.87M	-56.52M	12.73M	27.96M	38.86M	7.46M	13.36M	8.96M
Net Income	-91.92M	-232.62M	-133.13M	-55.18M	82.63M	-69.33M	26.88M	-70.41M
Income Tax Expense	2.50M	1.62M	13.66M	673K	0.00	0.00	312K	0.00
Net Profit Margin	-73.2%	-210.5%	-76.2%	-33.5%	30.0%	-56.5%	17.2%	-173.4%
EBITDA	-166.99M	-166.30M	-120.86M	-73.67M	51.26M	-71.00M	18.12M	-76.12M
EBITDA Margin	-133.0%	-150.5%	-69.2%	-44.8%	18.6%	-57.9%	11.6%	-187.5%
Depreciation & Amortization	10.51M	12.11M	11.50M	8.80M	7.49M	5.79M	4.30M	3.25M
EPS Basic	-1.24	-3.58	-2.08	-0.93	1.42	-1.11	0.48	-1.31
EPS Diluted	-1.24	-3.58	-2.08	-0.93	1.37	-1.11	0.46	-1.31
Weighted Average Basic Shares	74.24M	65.04M	60.50M	59.65M	58.38M	57.21M	56.53M	53.75M
Weighted Average Diluted Shares	74.24M	65.04M	60.50M	59.65M	60.50M	57.21M	58.47M	53.94M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.